Gain Therapeutics Presents Key Data on GT-02287 at FENS Forum 2024

BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. GANX, a clinical-stage biotechnology company at the forefront of creating innovative allosteric small molecule therapies, shared exciting data at the Federation of European Neuroscience Societies (FENS) Forum 2024. The company revealed positive outcomes from a preclinical study of GT-02287, demonstrating notable improvements in cognitive performance linked to GBA1 Parkinson's disease.

Discovering Next-Generation Therapeutics

Stepping up in the fight against protein misfolding diseases, GANX is utilizing their expertise to advance the development of their novel therapeutic, GT-02287. At the recent FENS Forum, GANX showcased a poster detailing the progress and potency of GT-02287 in addressing the complex challenges posed by diseases like Parkinson's. This model treatment has shown promising benefits in a preclinical setting, indicating potential for future clinical applications.

Breaking Ground in Biotechnology

Headquartered in Bethesda, Maryland, GANX is pioneering the exploration into allosteric modulators. The company's dedication to targeting diseases caused by misfolded proteins is not just a scientific pursuit; it's a ray of hope for patients struggling with neurological disorders across the globe. Their continuous efforts in research and development place GANX at the cutting edge of the biotechnology sector, potentially ushering in a new age of disease management and patient care.

Contributing to Scientific Discourse

Presenting their findings at a prominent event such as the FENS Forum is a testament to GANX's commitment to scientific discourse and collaboration. By sharing their work with the global scientific community, GANX supports the collective goal of understanding and ultimately conquering debilitating neurological diseases.

Gain, Therapeutics, Parkinson's